Accountable for leading all Research & Development activities within the company. Developing the R&D strategy and delivering a pipeline of pre-clinical and clinical stage oncology and immuno-oncology projects (Phase 1 through to preparations for Phase 3). Leading a team of senior functional experts to develop the existing project portfolio, expand LIDDS’ proprietary NanoZolid drug delivery technology platform, enhance organizational capabilities and deliver increased value through internal projects and external collaborations.Leading LIDDS Executive Management Team responsible for all business development activities, financing, budget setting and control, recruitment and talent management. Representing all R&D activities to the board of directors.

Led a portfolio of drug discovery and development projects in the Respiratory & Immunology therapy area at AZ. Role covered full time project leadership of all early discovery and clinical development activities, from Target Identification through to completion of Ph2B.Accountable for overall integrated drug development strategy, resource allocation, project budgets, timelines, Target-Product Profile, commercial positioning and delivering projects through internal milestones and investment governance decisions.Using influencing skills and stakeholder management to drive performance across internal matrixed functional lines and external organisations. Defining and executing the detailed operational activities required to effectively progress projects towards a launched medicine.

Early Development Leader (EDL) for the clinical development of two novel epigenetic drug candidates for inflammatory and dermatology indications – building expertise in both oral and topical drug development. Within GSK, the EDL is the 'Asset CEO', a leader of cross-functional, multi-national matrix teams who is accountable for the asset’s complete early development; establishing and delivering the clinical development strategy from commit to clinical candidate up to and including Ph2a proof of conceptMember of DPU Leadership Team responsible for contributing to unit and therapy area strategy, with day-to-day management of program portfolio, resource deployment and DPU talent poolAccountable for the leadership of drug discovery projects within the Epigenetics DPU portfolio, including personal leadership of assets as well as supporting DPU program leaders through key milestones (commit to target, lead op, candidate and FTiH)

Director of Medicinal Chemistry in the Epinova Epigenetics DPU (Immuno-Inflammation Therapy Area)Program, Project and Medicinal Chemistry leader with a focus on discovery of clinical candidates with an epigenetic mechanism.Member of DPU Leadership Team responsible for contributing to unit and therapy area strategy, with day-to-day management of program portfolio, resource deployment and DPU talent pool

Leader of multiple Immuno-Inflammation drug discovery projects, including early discovery activities and late lead optimisation efforts, deploying resource internally and externally through CROsProgram leader responsible for the establishment and prosecution of the novel Bromodomain target class within the DPU.

Research group head and Program Leader within Respiratory & Inflammation drug discovery unit. Created and led Lead Optimisation programs to deliver hits, leads and pre-candidates to portfolio projects.

Group Leader for Parallel Synthesis & Purification team

Discovery research chemist in Neuroscience drug targets.